The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH)

被引:9
|
作者
Salvoza, Noel [1 ,2 ]
Bedin, Chiara [3 ]
Saccani, Andrea [3 ]
Tiribelli, Claudio [1 ]
Rosso, Natalia [1 ]
机构
[1] Fdn Italiana Fegato, ONLUS, Area Sci Pk,Basovizza SS14 km 163 5, I-34149 Trieste, Italy
[2] DOST Bicutan, Philippine Council Hlth Res & Dev, Taguig 1631, Philippines
[3] AB Res SRL, Via Impresa 1, I-36040 Brendola, Italy
关键词
NAFLD; NASH; triterpenic acid; acteoside; in vitro models; FATTY LIVER-DISEASE; HEPATIC STELLATE CELLS; TORMENTIC ACID; GLOBAL EPIDEMIOLOGY; OXIDATIVE STRESS; PATHOGENESIS; INFLAMMATION; HEPATOCYTES;
D O I
10.3390/ijms23073562
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Triterpenic acid (TA) and acteoside (ACT), the major components of APPLIVER and ACTEOS, respectively, have been reported to exert hepatoprotective effects, but the molecular mechanisms remain elusive, particularly in the NAFLD/NASH context. We assessed their effects in our well-established in vitro model resembling the pathophysiological mechanisms involved in NASH. Human hepatocytes and hepatic stellate cells were exposed to free fatty acids (FFA) alone or in combination with APPLIVER and ACTEOS as a mono- or co-culture. Steatosis, inflammation, generation of reactive oxygen species (ROS), and collagen deposition were determined. ACTEOS reduced both the TNF-alpha and ROS production, and, most importantly, attenuated collagen deposition elicited by the excess of FFA in the co-culture model. APPLIVER also showed inhibition of both TNF-alpha production and collagen deposition caused by FFA accumulation. The compounds alone did not induce any cellular effects. The present study showed the efficacy of APPLIVER and ACTEOS on pathophysiological mechanisms related to NASH. These in vitro data suggest that these compounds deserve further investigation for possible use in NASH treatment.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Saroglitazar Shows Therapeutic Benefits in Mouse Model of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
    Jain, Mukul R.
    Giri, Suresh R.
    Bhoi, Bibhuti
    Trivedi, Chitrang
    Ranvir, Ramchandra
    Kadam, Shekhar
    Swain, Prabodha
    Patel, Pankaj R.
    [J]. DIABETES, 2015, 64 : A503 - A503
  • [32] Combining Genetic and Dietary Factors in Creation of a Novel Model of Nonalcoholic Steatohepatitis (NASH) in Mice
    Nelson, James E.
    Maliken, Bryan D.
    Dhillon, Barjinderjit K.
    Yeh, Matthew
    Beauchamp, M.
    Kowdley, Kris V.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S801 - S801
  • [33] Pioglitazone Improves Nonalcoholic Steatohepatitis (NASH) in a Diet-Induced Cynomolgus Monkey Model
    Camacho, Raul
    Polidori, David
    Chen, Tao
    Gao, Bin
    Wong, Peggy
    Gabriel, Joseph A.
    Zhu, Edward
    Wang, Tony
    Nawrocki, Andrea R.
    [J]. DIABETES, 2020, 69
  • [34] Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
    Tadashi Namisaki
    Ryuichi Noguchi
    Kei Moriya
    Mitsuteru Kitade
    Yosuke Aihara
    Akitoshi Douhara
    Norihisa Nishimura
    Kosuke Takeda
    Yasushi Okura
    Hideto Kawaratani
    Hiroaki Takaya
    Kenichiro Seki
    Hitoshi Yoshiji
    [J]. Journal of Gastroenterology, 2016, 51 : 162 - 172
  • [35] Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
    Namisaki, Tadashi
    Noguchi, Ryuichi
    Moriya, Kei
    Kitade, Mitsuteru
    Aihara, Yosuke
    Douhara, Akitoshi
    Nishimura, Norihisa
    Takeda, Kosuke
    Okura, Yasushi
    Kawaratani, Hideto
    Takaya, Hiroaki
    Seki, Kenichiro
    Yoshiji, Hitoshi
    [J]. JOURNAL OF GASTROENTEROLOGY, 2016, 51 (02) : 162 - 172
  • [36] EFFECTS OF L-CARNITINE SUPPLEMENTATION ON BODY COMPOSITION IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)
    Amiri-Moghadam, Shirin
    Nematy, Mohsen
    Eghtesadi, Shayryar
    Khalili, Mohammad
    Mojarrad, Majid
    Jazayeri, Shima
    Vosooghinia, Hasan
    Khosravi, Ahmad
    Salehi, Maryam
    Beheshti-Namdar, Ali
    [J]. CURRENT TOPICS IN NUTRACEUTICAL RESEARCH, 2015, 13 (02) : 71 - 76
  • [37] Comparative efficacy of obeticholic acid and INT-767 in the Gubra mouse NASH model of diet induced and biopsy-confirmed nonalcoholic steatohepatitis (NASH)
    Roth, Jonathan D.
    Feigh, Michael
    Veidal, Sanne Skovgaard
    Fensholdt, Louise Kathrine Due
    Vrang, Niels
    Young, Mark
    [J]. HEPATOLOGY, 2017, 66 : 1060A - 1060A
  • [38] Beneficial effects of UDCA and Ncx-1000 alone or in combination with vitamin E in a nonalcoholic steatohepatitis rat model
    Haddad, Yara
    Vallerand, Diane
    Brault, Antoine
    Spenard, Jean
    Haddad, Pierre S.
    [J]. GASTROENTEROLOGY, 2008, 134 (04) : A780 - A781
  • [39] Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis
    Ma, Taotao
    Huang, Cheng
    Zong, Guojun
    Zha, Dajun
    Meng, Xiaoming
    Li, Jun
    Tang, Wenjian
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 63 (04) : 587 - 593
  • [40] EFFECTS OF INDIVIDUAL BILE ACID FEEDING ON NONALCOHOLIC STEATOHEPATITIS DEVELOPMENT IN LOW BILE ACID MOUSE MODEL
    Taylor, Rulaiha E.
    Meadows, Vik
    Capece, Gina
    Basaly, Veronia
    Henry, Zakiyah
    Otersen, Katherine D.
    Kong, Bo
    Guo, Grace L.
    [J]. HEPATOLOGY, 2023, 78 : S1087 - S1088